INNOVACAP · Healthcare · Drug Manufacturers - Specialty & Generic
Composite scorecard: 41/100 — Quality 51 · Valuation 18 · Momentum 57
| Share price | ₹973.25 |
| Market cap | ₹5,662 Cr |
| P/E ratio | 40.2 |
| P/B ratio | 5.2 |
| ROE | 22.0% |
| ROCE | 15.3% |
| Dividend yield | 0.40% |
| Book value | ₹190.62 |
| Year | Sales | Net profit | OPM |
|---|---|---|---|
| 2026 | ₹1,630 Cr | ₹141 Cr | 15.0% |
| 2025 | ₹1,244 Cr | ₹128 Cr | 15.0% |
| 2024 | ₹1,081 Cr | ₹94 Cr | 14.0% |
| 2023 | ₹926 Cr | ₹68 Cr | 12.0% |
| 2022 | ₹801 Cr | ₹64 Cr | 12.0% |
Innova Captab Limited, an integrated pharmaceutical company, engages in the research and development, manufacture, distribution, and marketing of drugs and pharmaceutical products in India and internationally. The company provides contract development and manufacturing organization services to Indian pharmaceutical companies. It is also offers various generic formulation products, including cephalosporins, proton pump inhibitor, anticholinergic and heparin NSAIDs, analgesics and antipyretic, anticold and antiallergic, antiemetic, antidiabetic, antispasmodic, antifibrinolytic, cardiovascular, a